1 research outputs found
Growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula in infants with cowβs milk protein allergy
ObjectiveTo evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cowβs milk protein allergy (CMPA).MethodsA total of 226 infants (meanβΒ±βSD age: 106.5βΒ±β39.5 days, 52.7% were girls) with CMPA who received eHCF comprising at least half of the daily dietary intake were included. Data on anthropometrics [weight for age (WFA), length for age (LFA) and weight for length (WFL) z-scores] were recorded at baseline (visit 1), while data on infant feeding and stool records, anthropometrics and Infant Feeding and Stool Patterns and Formula Satisfaction Questionnaires were recorded at visit 2 (on Days 15βΒ±β5) and visit 3 (on Days 30βΒ±β5).ResultsFrom baseline to visit 2 and visit 3, WFA z-scores (from β0.60βΒ±β1.13 to β0.54βΒ±β1.09 at visit 2, and to β0.44βΒ±β1.05 at visit 3, pβ<β0.001) and WFL z-scores (from β0.80βΒ±β1.30 to β0.71βΒ±β1.22 at visit 2, and to β0.64βΒ±β1.13 at visit 3, pβ=β0.002) were significantly increased. At least half of infants never experienced irritability or feeding refusal (55.7%) and spit-up after feeding (50.2%). The majority of mothers were satisfied with the study formula (93.2%), and wished to continue using it (92.2%).ConclusionsIn conclusion, eHCF was well-accepted and tolerated by an intended use population of infants ββ€β6 months of age with CMPA and enabled adequate volume consumption and improved growth indices within 30 days of utilization alongside a favorable gastrointestinal tolerance and a high level of parental satisfaction